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A B S T R A C T 17 
 18 
Despite the abundant use of polyethylene oxides (PEOs) and their integration as an excipient 19 
in numerous pharmaceutical products, there have been no previous reports of applying this 20 
important thermoplastic polymer species alone to fused deposition modelling (FDM) 3D 21 
printing. In this work, we have investigated the manufacture of oral doses via FDM 3D printing 22 
by employing PEOs as a backbone polymer in combination with polyethylene glycol (PEG). 23 
Blends of PEO (molecular weight 100K, 200K, 300K, 600K or 900K) with PEG 6K 24 
(plasticiser) and a model drug (theophylline) were hot-melt extruded. The resultant filaments 25 
were used as a feed for FDM 3D printer to fabricate oral dosage forms (ODFs) with innovative 26 
designs. ODFs were designed in a radiator-like geometry with connected paralleled plates and 27 
inter-plate spacing of either 0.5, 1, 1.5 or 2 mm. X-ray diffraction patterns of the filaments 28 
revealed the presence of two distinctive peaks at 2θ = 7° and 12°, which can be correlated to 29 
the diffraction pattern of theophylline crystals. Varying blends of PEO and PEG allowed the 30 
formation of mechanically resistant filaments (maximum load at break of 357, 608, 649, 882, 31 
781 N for filament produced with PEO 100K, 200K, 300K, 600K or 900K, respectively). 32 
Filaments of PEO at a molecular weight of 200-600K were compatible with FDM 3D printing 33 
process. Further increase in PEO molecular weight resulted in elevated shear viscosity (>104 34 
Pa.S) at the printing temperature and hindered material flow during FDM 3D printing process. 35 
A minimal spacing (1 mm) between parallel plates of the radiator-like design deemed essential 36 
to boost drug release from the structure. This is the first report of utilising this widely used 37 
biodegradable polymer species (PEOs and PEG) in FDM 3D printing. 38 
  39 
A R T I C L E    I N F O 40 
Keywords: 41 
Personalised medicine, additive manufacturing, complex structures, tablets, patient-specific, structural 42 
design.  43 
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1. Introduction 44 
Through recent advances in pharmacogenetics the relationship between an individual’s 45 
genome, their genetic predisposition to disease and their response to specific medications is 46 
increasingly understood [1]. With an increased focus on patient-centred and stratified 47 
treatment, there is a growing need for a technological solution to provide individual patients 48 
with reliable and safe personalised dosage forms. In the last few years, additive manufacturing 49 
has been proposed as alternative platform for on-demand production of personalised dosage 50 
forms with significant ability to tailor the size, shape, dose as well as drug release pattern [2-51 
4]. 52 
Among other commercially available technologies, fused deposition modelling (FDM) 3D 53 
printing offers major advantages, including the low cost of the printer, the absence of finishing 54 
steps and the lack need for powder facilities. These properties position FDM 3D printing as a 55 
very attractive platform for small-scale individualising for solid dosage forms. Recently, 56 
several examples of the use of FDM 3D printing for production of immediate, delayed and 57 
extended drug release have been reported [3, 5-9]. The technology proved efficacy at accurately 58 
titrating coumarin doses in animals [10] and extended drug release in gastro-retentive systems 59 
[11]. 60 
For the pharmaceutical industry to make a full use of 3D printing, it is essential to adapt 61 
pharmaceutical grade polymers for FDM 3D printing. Previous studies have used cellulose, 62 
methacrylate, acrylic acid or PVP derivatives to produce solid dosage forms [12]. PEO is one 63 
of the most commonly used polymers in pharmaceutical industry. PEO is commercially 64 
available between 100K to 10,000K g/mole and has been extensively used for oral and parental 65 
formulations (Gullapalli and Mazzitelli, 2015). PEOs have been commonly used to produce 66 
extended release tablets in powder compression Moroni and Ghebresellassie, 1995), hot melt 67 
extrusion (Zhang and McGinity, 1999) and in buccal tablets (Apicella et al., 1993). However, 68 
limited reports are available applying this extensively used polymer species to FDM 3D 69 
printing. In rare examples, PEO was used for formation of thin oral film in combination with 70 
other additives [13], or as an additive to methacrylate polymer for 3D printing of tablets [14].  71 
In order for a filament to be compatible with the FDM 3D printing process, it requires critical 72 
mechanical and rheological criteria [15]. Previous studies have linked a filament’s 3D printing 73 
compatibility with the rheological properties of the backbone polymers: poly methacrylate [8], 74 
PVA [16] and PVP-VA [16, 17]. The availability of PEOs at different molecular weight grades 75 
4 
 
provides the opportunity to test the impact of polymeric molecular weight and rheological flow 76 
properties of a single polymer.  77 
In this work, we have investigated the fabrication of oral doses via FDM 3D printing by 78 
employing PEOs as a backbone polymer in combination with PEG as a plasticiser. We assessed 79 
the impact of polymer molecular weight on the mechanical properties of the resultant filaments 80 
and their rheological properties. We have also tested the effect of an innovative radiator-like 81 
design of the solid dosage form on the acceleration of drug release patterns. 82 
2. Materials and Methods 83 
2.1 Materials 84 
Theophylline was supplied by Acros Organics (UK). Polyethylene glycol (PEG 6000) and all 85 
grades of polyethylene oxide (PEO) were purchased from Sigma-Aldrich (Dorset, UK).  86 
2.2 Preparation of filaments using hot melt extrusion (HME) 87 
Filaments were prepared by mixing polyethylene oxide (PEO molecular weight of 100K, 200K, 88 
300K, 600K, or 900K), Polyethylene Glycol (PEG 6K) and theophylline (Table 1). The 89 
mixtures were extruded using a Thermo Scientific HAAKE MiniCTW hot melt extruder 90 
(Karlsruhe, Germany) after mixing inside the extruder for 5 min at a temperature range of 60-91 
80°C (Table1) at 35 rpm using 1.5 mm nozzle. 92 
2.3 Tablet design and printing 93 
Tablets were designed using Autodesk® 3ds Max Design 2016 software version 18.0 94 
(Autodesk, Inc., USA). In the CAD design, the radiator-like tablets were structured with increasing 95 
inter-plate spacing of 5, 10, 15 or 20 mm whilst the overall dimensions of the design were maintained 96 
within the volume of 20106 mm. The templates were then imported into the 3D printer software 97 
in a stereolithography (.stl) file format. The previously extruded filaments were fed into the 98 
FDM 3D printer equipped with 0.4 mm nozzle size and MakerWare Version 2.4.0.17 99 
(Makerbot Industries, LLC, USA). Tablets were printed using modified settings of the software 100 
as described earlier in our previous work [18]:Replicator 2X; type of filament: PLA; resolution: 101 
standard; temperature of building plate: 40 °C; speed of extruder 50 mm/sec while extruding 102 
and 150 mm/sec while traveling; infill: 100%; height of the layer: 200 µm. The temperature of 103 
the nozzle for each filament is specified in Table 1.  104 
2.4 Thermal analysis 105 
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Thermal decomposition profiles for PEOs as both received and extruded filaments were 106 
measured using a TA Q500 Thermogravimetric Analyzer TGA (TA Instruments, Elstree, 107 
Hertfordshire, UK). Samples with an average weight of 10 mg were measured from 25°C to 108 
500°C with a heating rate of 10°C/min and a nitrogen gas purge of 40/60 mL/min for 109 
sample/furnace respectively. The thermal behaviour of these samples was measured using a 110 
TA Q2000 Differential Scanning Calorimeter (DSC) (TA Instruments, Elstree, Hertfordshire, 111 
UK). Samples (5 mg) were prepared in aluminium standard pans (40 µL) and sealed with pin-112 
holed lid. Each sample was heated from -10 to 255oC at 10°C/min under a nitrogen purge of 113 
50 mL/min. Data from TGA and DSC were analysed using a TA 2000 analysis software (TA 114 
Instruments, Elstree, Hertfordshire, UK). All measurements were carried out in triplicate. 115 
 116 
2.5 X-ray Powder diffractometry (XRPD) 117 
An X-ray powder diffractometer, D2 Phaser with Lynxeye (Bruker, Germany) was used to 118 
assess the physical form of theophylline, PEO, PEG and drug loaded filaments. Samples were 119 
scanned from (2θ) = 5° to 50° using 0.01° step width and a 1 second time count. The X-ray 120 
wavelength of 0.154 nm was used using a Cu source and a voltage of 30Kv. The divergence 121 
slit was 1 mm and the scatter slit 0.6 mm. Filament emission was 10 mA using a scan type 122 
coupled with a two theta/theta scintillation counter over 60 min. 123 
2.6 Hansen solubility parameter 124 
Hansen solubility parameters for the polymer and the drugs were calculated using HSPiP 125 
software (version 5.0.08). 126 
2.7 Scanning electron microscopy (SEM) 127 
The topography of the drug-loaded filaments and the 3D printed tablets were examined using 128 
Quanta-200 SEM microscope at 20 kV. Samples were coated under vacuum with a gold coater 129 
JFC-1200 Fine Coater (Jeol, Tokyo, Japan). In addition, photographs of tablets were collected 130 
a Canon EOS-1D Mark IV (Canon Ltd, Japan). 131 
2.8 Rheology studies 132 
A shear Physica MCR 501 rheometer (Anton Paar, Germany) was used in oscillation mode 133 
with a parallel plate configuration (plate diameter = 25mm). The gap between the plate and the 134 
base was set at 0.5 mm. Amplitude sweep test was performed to determine the linear 135 
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viscoelastic region (LVR). Afterwards, frequency sweep tests were performed at a strain 136 
amplitude of 1% (Well within the LVR region) and an angular frequency range from 100 to 137 
0.1 rad/sec. Each sample was tested at three temperatures; 100, 110 and 140°C. The readings 138 
(n = 6) were recorded for each frequency decade (18 points in total). The test was only carried 139 
out after the normal force recorded by the device dropped below 1N, which indicates that the 140 
polymer is in a relaxed state. Power law fit was used in the linear shear thinning area of the 141 
obtained rheological data to measure the shear-thinning index (𝑛). Elastic (G’) and viscous 142 
(G”) moduli as well as complex viscosity data were recorded and plotted against the angular 143 
frequency at each temperature.  144 
2.9 Tensile strength studies 145 
A tensile strength testing system 5568 (Instron, Buckinghamshire, UK) was used to measure 146 
the breaking stress for filaments with irregular geometry with an average diameter of 147 
approximately 1.8 and 10mm gauge length. The diameter of the samples was measured using 148 
a Vernier micro-caliper for various sections and the average (c.a. 1.8 mm) was programmed 149 
into the software. The deformation rate (extension) was set to 20 mm/min and the data were 150 
collected every 50 msec. A sand paper was used to prevent the slipping of the sample from the 151 
clamp. Samples that showed signs of slipping from the clamp were rejected and all samples 152 
were measured in triplicate. A stress strain graph was plotted for each sample and the breaking 153 
stress was measured. 154 
2.10 Drug Contents and in vitro drug release studies 155 
For assessment of theophylline contents, oral doses were dissolved in 500 mL of deionised water and 156 
were stirred consciously for one hour at 40 oC until complete dissolution. Samples were filtered through 157 
a 0.22 μm Millex-GP syringe filter (Merck Millipore, USA) and the concentration of the drug was 158 
determined using a Jenway Spectrophotometer (Bibby Scientific Ltd, UK) at λ max of 272 nm (n=3). 159 
To study in vitro theophylline release for 3D printed tablets, An AT 7 Smart USP II dissolution test 160 
apparatus (Sotax, Switzerland) was used. A dissolution medium of 900 mL 0.1M HCl (pH 1.2) at 161 
37±0.5 °C with a paddle speed of 50 rpm was used for 2 hours. Each experiment was carried out in 162 
triplicate. Samples were collected at 5 min intervals and drug concentration was determined using 163 
UV/VIS spectrophotometer (PG Instruments Limited, UK) at the wavelength of 272 nm and path length 164 
of 10 mm and outcome data were analysed using IDISis software 2012 (Automated Lab, UK). 165 
2.11 Statistical analysis 166 
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The data were analysed by one-way ANOVA using SPSS Software (22.0.0.2). The level of 167 
attributed significance for comparisons were as follows: p > 0.05 not significant; p≤0.05 168 
significant. 169 
  170 
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3. Results and discussion 171 
Polyethylene glycol (PEG) and polyethylene oxide (PEO) are two of the most widely used excipients 172 
in pharmaceutical products. Both products are also used in other healthcare applications. Both polymers 173 
are also biodegradable and suitable to be used as a polymeric biomaterial in tissue scaffolding [19]. 174 
PEGs are considered a safe choice to prepare hydrogel sealant for patients undergoing surgery [20] and 175 
are also used in the manufacturing of 3D porous scaffolds [21]. Optimisation of pharmaceutical solid 176 
dosage forms produced by FDM 3D printing requires a suitable and compatible polymer backbone for 177 
the feed filament.  Initially, PEGs were first assessed producing feed filaments for FDM 3D printing 178 
(as a backbone polymer). However, the hot melt extrusion process only yielded easily breakable PEG-179 
based filaments which lacked the required rheological and mechanical properties to enable for the use 180 
of PEGs in FDM 3D printing of solid dosage forms (data not shown). Therefore, a higher molecular 181 
weight thermoplastic polymer (PEO), was used for its mechanical and rheological properties while PEG 182 
was added as a plasticiser to facilitate the material flow and pore former to accelerate drug release from 183 
the dosage form produced by FDM 3D printing.  184 
The thermal properties of PEOs of different molecular weights (100K-900K) were shown to be stable 185 
at <150oC (Fig. 1A). In addition, PEO revealed a minimum moisture content with a weight loss of <2% 186 
at 120°C. The polymer showed no significant change in thermal degradation following the 187 
compounding into a filament with the addition of PEG and theophylline via HME extrusion (Fig. 1B). 188 
Pourepolymer melting was observed above 66-69°C (data not shown) [22]. However, the compounded 189 
filament produced in this study showed slightly lower melting points (in the range of 62-65.9 oC), which 190 
could be attributed to the addition of a lower melting point additive (PEG) (Fig. 1C). Thermal profiles 191 
also illustrated that theophylline was crystalline within the polymer matrix with the appearance of 192 
theophylline melting endotherm known to be at ~240°C [23].  193 
XRD patterns confirmed the crystallinity status of PEO 200K and PEG 6K with the presence of intensity 194 
peaks at 2θ = 19.1o and 23.2o the appearance of these peaks in the pattern of HME compounded filament 195 
suggests that polymers remained crystalline. The diffraction patterns of extruded filaments also revealed 196 
diffraction peaks at 2θ = 7° and 12.9° (Fig. 3). The later peaks are characteristic peaks in the diffraction 197 
pattern of theophylline [7]. This confirms the crystalline structure of theophylline within the polymeric 198 
matrix. The diffraction patterns of filaments produced with other molecular weight PEOs (100K, 300K, 199 
600K and 900K), also revealed the presence of crystalline theophylline (Supplementary data, Figs. S1-200 
4). 201 
The Hansen solubility parameter data of the PEO and PEG blend and the drug are shown in Table 2. 202 
The difference in solubility parameter between the PEO and PEG blend and the drug (Δδ=7 MPa1/2), 203 
indicated a minimal miscibility between these molecules and predicted the presence of theophylline as 204 
a solid suspension within PEG/PEO polymeric matrix. 205 
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The impact of molecular weight on mechanical properties of HME compounded filaments was assessed 206 
using the tensile strength test (Fig. 3A). HME compounded filaments including PEO of 100K molecular 207 
weight showed the least maximum load before break (357N) (p<0.05) and were deemed too fragile. As 208 
the filament breaks instantly upon the application of gear pressure in the FDM 3D printer’s head. HME 209 
compounded filaments including PEO of 200K molecular weight were able to be loaded through the 210 
gears of the FDM 3D printer head. However, frequent breakage of the filament due to the pressure of 211 
the gears interrupted the printing process and resulted in printing failure. When HME compounded 212 
filaments containing PEO of higher molecular weight (300K, 600K and 900K), the filaments were able 213 
to withstand higher tension (Fig. 3A). The maximum load at break steadily increased with longer 214 
polymer chains [24]. On the other hand, Young modulus of PEO 100K based filament reveal more 215 
brittle behaviour in comparison to filaments produced with higher molecular weight PEO (Fig. 3B). 216 
The increased plasticity of HME compounded filaments containing higher molecular weight PEO also 217 
allows the filament to withstand more pressure from the gears of the head of the FDM 3D printer and 218 
mitigates the risk of filament breakage. This increase in the strength of the filament can be related to 219 
previous observations of the reduced mobility due to the entanglement of the amorphous parts of the 220 
polymeric chains associated with an  increase in the chain length [25]  221 
During the FDM 3D printing process, the filament passed through lead to a hot channel that terminates 222 
in a nozzle and while the path is narrowed from 1.75 to 0.4 mm (nozzle diameter), the filament 223 
experiences an increase from room temperature to the printing temperature (110-145 oC). Therefore, it 224 
is essential to study the rheological behaviour of the filament compositions at the temperature of the 225 
printing nozzle. Hence, complex viscosity under various angular frequency at two representative 226 
printing temperatures (110 and 145 °C) were performed (Fig. 4). Complex viscosity of a polymer is a 227 
temperature-dependent material property [26]. Despite the similarity of the melting points across all 228 
PEO grades, the printability of each filament using FDM 3D printing was dependent on the temperature 229 
of the 3D printer temperature (Table 1). The lower complex viscosities of PEO 100K (539.8 Pa.S) and 230 
200K (1385.31 Pa.S) based filaments  suggest possible flow from the hot nozzle of the 3D printer (Fig. 231 
5). However, it was not possible to physically test 3D printing using these filaments due to their 232 
incompatibility with the gears of the 3D printer’s head (see above). However, HME compounded 233 
filaments including PEO of higher molecular weights allowed consistent flow from the hot nozzle at a 234 
printing temperature of 110 and 145°C for PEO 300K and 600K respectively (Fig. 5). The complex 235 
viscosity of these filaments was in the range of 9000 and 10000 at the corresponding temperature at 1% 236 
angular viscosity. Filament containing higher molecular weight PEO (900K) was observed to have a 237 
high complex viscosity (>22610 Pa.S) and was associated with restricted materials flow in the nozzle 238 
of the 3D printer and obstructed the printing of this particular filament. Further increase in nozzle 239 
temperatures (up to 220oC), did not improve material flow of this specific HME compounded filament. 240 
This may be because increasing temperature above 150 °C is likely to accelerate PEO degradation [27]. 241 
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It can be deduced that a complex viscosity of approximately <8000 Pa.S is necessary to achieve 242 
sufficient material flow from the FDM 3D printer hot nozzle and successful completion of FDM 3D 243 
printing.  244 
The viscoelastic properties of the filaments produced with PEOs of different MW were characterised 245 
through the measurement of the storage G` and loss modulus G`` (Fig. 6). In general, increasing the 246 
temperature led to a decrease in both storage modulus G` and loss modulus G`` across different 247 
molecular weights. Filaments containing PEO 100K were noticed to be in a terminal flow zone as 248 
G``>G`. A higher PEO molecular weight in the filament resulted in less liquid-like flow and a more 249 
elastic behaviour as the polymer was approaching crossover point. Following extrusion from the nozzle 250 
of the 3D printer, the filament loses its microstructure and conforms to the architecture dictated by the 251 
CAD design and slicing engine. This behaviour can be advantageous in FDM 3D printing as it provides 252 
a wide variety of molecular weights to select from while maintaining the same release profile. This 253 
observation needs to be repeated and validated with other drugs that may interact with PEO.  254 
Unlike regular caplet design, where filaments are not only fused with lower and upper layers, but also 255 
with side printed layers, the radiator-like design only allows fusion with upper and lower layers, leading 256 
to potentially different mechanical behaviour to solid caplet design. However, it was not possible to 257 
measure the tensile strength of oral doses due to their thin structure, where weak clamping point of the 258 
structures deemed it unsuitable for the test.  259 
When theophylline release from capsule-shaped tablets with PEO 600K produced by FDM 3D printing 260 
was assessed (Supplementary data, Fig. S2), a slow release profile was observed. It is likely that the 261 
drug is released though erosion of the polymeric matrix and diffusion mechanisms [28]. The polymer-262 
rich structure of the caplet hindered drug release. The fast hydration of PEO/PEG based tablets produced 263 
by  powder compression was reported to yield a gel-layer upon introduction to dissolution medium that 264 
significantly prolongs drug release [29]. In fact, PEO/PEG blends have been devised to produce tablet 265 
with extended release over 12-24 hours [30]. In such matrix systems, drug release is dependent on the 266 
rate of polymer dissolution [31], which regulates the pattern of drug release and often yields a zero 267 
order pattern [32]. 268 
In order to accelerate drug release from PEO matrix, an alternative novel design approach of a radiator-269 
like architecture was evaluated (Fig. 7). The proposed geometry allows 7-8-fold increase in surface-to-270 
mass ratio of the structure (Table 3). Moreover, the design facilitates water penetration and drug 271 
permeation from the PEO matrix by minimizing the thickness of gel-layer with the use of low-thickness 272 
plates. Four designs with identical overall dimensions but with increasing spaces (0.5, 1.0, 1.5 and 2.0 273 
mm) between the design plates were tested. With increasing inter-plate spacing within the dimensions 274 
20106 mm, the number of plates has decreased and resulted in lower printed mass and dose (Fig. 7, 275 
Table 3). A minimum spacing of 1 mm was deemed essential to accelerate drug release from the 276 
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structure and meet USP criteria for immediate release products (Fig. 8A). Similar drug release was 277 
obtained within the FDM 3D-printable range of PEOs (200K-600K) (Fig. 8B). Following introduction 278 
to the dissolution apparatus, the PEO matrix hydrates and swells leading to significant growth in the 279 
thickness of the radiator plate. Despite similar surface-to-mass ratio of these oral dose designs (Table 280 
3), the 0.5mm spaced design appeared to be slower in comparison with the rest of designs. It is possible 281 
that such swelling in the 0.5 mm-spaced design resulted in plate adhesion, leading to reduction of 282 
contact surface area with the dissolution medium and hence slowing drug release. The paper provides 283 
a unique example of how 3D printing and novel design approach can significantly alter the release 284 
profile of the same formulation. The use of radiator-like design maximised interaction with dissolution 285 
medium and prevented the formation of thick permission gel layer, which will slow down drug release. 286 
In the future, such design approach will help to personalise the release profile without the need to 287 
modify the formulation.  288 
Conclusion 289 
This work demonstrates the effect of PEO molecular weight on the compatibility of HME compounded 290 
filaments for FDM 3D printing. A molecular weight of PEO between 300K-600K was shown to have 291 
optimal mechanical and rheological properties for the FDM 3D printing process. A lower molecular 292 
weight of PEO (100K-200K) yielded mechanically incompatible HME compounded filaments and a 293 
larger molecular weight of PEO (900K) contributed to significantly high complex viscosity and 294 
inhibited material flow. The use of a relatively low printing temperature 105-145 oC potentially extends 295 
the applicability of this technology to a wider range of active pharmaceutical ingredients. A novel 296 
radiator-like paralleled plate geometry oral doses containing widely used biodegradable polymer 297 
species (PEOs and PEG) was reported. By using this architecture, it was possible to accelerate drug 298 
release and overcome polymer hindrance of theophylline release through PEO swelling and erosion. 299 
These findings are essential in the development of next-generation personalised drug delivery doses 300 
using specialised polymer/polymer blends purposely optimised for FDM 3D printing. 301 
 302 
  303 
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List of Figures 381 
Figure 1. TGA thermal decomposition profile of: A) raw PEO powder with molecular weights 382 
(100K, 200K, 300K, 600K, and 900K), B) hot melt extruded filaments containing 30 % 383 
theophylline, 35% PEG 6K, and 35% PEO (100K, 200K, 300K, 600K, and 900K), and C) DSC 384 
thermographs of corresponding filaments. 385 
Figure 2. Representative XRD diffraction patterns of raw theophylline, PEG 6K, raw PEO 386 
200K, and hot melt extruded filament containing 35% PEO200K, 35% PEG 6K, and 30% 387 
theophylline (for other grades, see Figure S1 in Supplementary Data) 388 
Figure 3. Tensile strength data of A) maximum load at break and B) Young Modulus for hot 389 
melt extruded filaments containing 30 % theophylline, 35% PEG 6K, and 35% PEO (100K, 390 
200K, 300K, 600K, and 900K). 391 
Figure 4 Shear index for filaments containing 30 % theophylline, 35% PEG 6K, and 35% PEO 392 
(100K, 200K, 300K, 600K, and 900K) at 110 and 145 oC. 393 
Figure 5 Shear rheometer data of complex viscosity for filaments containing 30 % theophylline, 394 
35% PEG 6K, and 35% PEO (100K, 200K, 300K, 600K, and 900K) at A) 110 and B) 145 oC. 395 
Figure 6 Shear rheometer data of storage modulus and loss modulus for filaments containing 396 
30 % theophylline, 35% PEG 6K, and 35% PEO (100K, 200K, 300K, 600K, and 900K) at A) 397 
110 and B) 145 oC. 398 
Figure 7 (A1) Rendered image and (A2) photograph of radiator-like design. (B1) Top view , 399 
(B 2) side view and (B3) photograph of radiator-like doses based on theophylline :PEG 400 
6K:PEO 600K 30:35:35. 401 
Figure 8 In vitro release pattern of: A) 0.6mm, 1.0mm, 1.5mm, and 2.0mm spaced radiator-402 
like 3D printed tablet containing 30 % theophylline, 35% PEG 6K, and 35% PEO 600K, and 403 
B) tablets prepared using filaments composed of 30 % theophylline, 35% PEG 6K, and 35% 404 
PEO 600K. 405 
List of Tables 406 
Table 1 Composition, processing temperatures and FDM 3D printing compatibility of 407 
theophylline filament based on PEO with different molecular weights. 408 
Table 2 Solubility parameter and its components of theophylline and PEO/PEG in MPa1/2. 409 
Table 3 410 
 411 
Supplementary Data  412 
Figure S1a  XRPD patterns of 30 % theophylline, 35% PEG 6K, and 35% PEO (100K, 413 
200K, 300K, 600K, and 900K. 414 
Figure S1b  XRPD patterns of: A) raw theophylline, raw PEG 6K, raw PEO 100K, and 415 
filament containing 30:35:35 theophylline:PEG 6K:PEO 100K, B) raw theophylline, raw 416 
PEG 6K, raw PEO 200K and 30:35:35 theophylline:PEG 6K:PEO 200K. 417 
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Figure S1c  XRPD patterns of raw theophylline, raw PEG 6K, raw PEO 300K, and filament 418 
containing 30:35:35 theophylline:PEG 6K:PEO 300K. 419 
Figure S1d  XRPD patterns of raw theophylline, raw PEG 6K, raw PEO 600K, and filament 420 
containing 30:35:35 theophylline:PEG 6K:PEO 600K. 421 
Figure S1e  XRPD patterns of raw theophylline, raw PEG 6K, raw PEO 900K, and filament 422 
containing 30:35:35 theophylline:PEG 6K:PEO 900K. 423 
Figure S2 In vitro release pattern of A) theophylline from FDM 3D printed caplet tablet and a 424 
radiator-like dose with spacing of 2 mm (theophylline: PEG 6K: PEO 600K 30:35:35). 425 
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